TBS and Dicerna Pharmaceuticals have been partners for the past six years. The Pharmaceutical company has seen some significant growth over the past few years as well as going public at the start of 2014.
TBS has been the sole management IT company since the inception of the firm and now will be managing the move into a brand new facility in a few months. Our onsite technicians along with our backend support staff have been planning the move for months to ensure a smooth transition.
Dicerna Pharmaceuticals is a biopharmaceutical company focused on the discovery and development of innovative treatments for rare inherited diseases involving the liver and for cancers that are genetically defined. Dicerna is using a proprietary RNA interference (RNAi) technology platform, which the Company believes improves upon existing RNAi technologies, to build a broad pipeline in these therapeutic areas.